ALEC - Alector Inc Stock Price, Fair Value and News

$1.86+0.08 (+4.49%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

ALEC Price Action

Last 7 days

-5.6%

Last 30 days

-48.8%

Last 90 days

-67.6%

Trailing 12 Months

-76.7%

ALEC RSI Chart

ALEC Valuation

Market Cap

182.2M

Price/Earnings (Trailing)

-1.15

Price/Sales (Trailing)

2.96

Price/Free Cashflow

-0.82

ALEC Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ALEC Fundamentals

ALEC Revenue

Revenue (TTM)

61.5M

Rev. Growth (Yr)

68.43%

Rev. Growth (Qtr)

1.72%

ALEC Earnings

Earnings (TTM)

-158.4M

Earnings Growth (Yr)

5.07%

Earnings Growth (Qtr)

-9.16%

ALEC Profitability

Return on Equity

-133.19%

Return on Assets

-30.7%

Free Cashflow Yield

-122.02%

ALEC Investor Care

Shares Dilution (1Y)

16.40%

Diluted EPS (TTM)

-1.7

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	96.4M	55.3M	61.5M	0
2023	125.7M	102.1M	96.3M	97.1M
2022	227.4M	300.7M	133.2M	133.6M
2021	18.0M	21.4M	197.9M	207.1M
2020	22.8M	19.0M	22.2M	21.1M
2019	28.4M	28.2M	24.4M	21.2M
2018	8.4M	15.2M	21.6M	27.7M
2017	1.2M	2.1M	2.9M	3.7M
2016	0	0	0	416.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Alector Inc

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its pipeline products include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001, AL002, and AL101 to treat neurodegenerative diseases. Alector, Inc. was founded in 2013 and is headquartered in South San Francisco, California.

CEO	Dr. Arnon Rosenthal Ph.D.
WEBSITE	alector.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	239

Alector Inc Frequently Asked Questions

What is the ticker symbol for Alector Inc? What does ALEC stand for in stocks?

ALEC is the stock ticker symbol of Alector Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Alector Inc (ALEC)?

As of Fri Dec 20 2024, market cap of Alector Inc is 182.15 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ALEC stock?

You can check ALEC's fair value in chart for subscribers.

Is Alector Inc a good stock to buy?

The fair value guage provides a quick view whether ALEC is over valued or under valued. Whether Alector Inc is cheap or expensive depends on the assumptions which impact Alector Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ALEC.

What is Alector Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, ALEC's PE ratio (Price to Earnings) is -1.15 and Price to Sales (PS) ratio is 2.96. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ALEC PE ratio will change depending on the future growth rate expectations of investors.